Health Condition 1: D898- Other specified disorders involving the immune mechanism, not elsewhere classified
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Control Intervention1: Nil: Nil
Control Intervention2: Nil: Nil
Sponsors
Tata Memorial Centre
Eligibility
Inclusion criteria
Inclusion criteria: All patients admitted for allogenic hematopoietic stem cell transplant from January 2008 to December 2020
Exclusion criteria
Exclusion criteria: Patients having active gastrointestinal bleed at the time of allogenic hematopoietic stem cell transplant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| -Time to defervescence in all groups Pansensitive, ESBL, MDR,VRE -Time to defervescence according to empirical antibiotic use versus surveillance stool culture guided 1st line antibiotics Timepoint: 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| -Time to change to second line antibiotics. -Concordance rate between blood culture during first febrile neutropenia episode and baseline stool surveillance culture. -Change in surveillance stool culture from pan sensitive to ESBL or CRO -Change in surveillance stool culture from ESBL at baseline to CRO -Change in surveillance stool culture from VSE to VRE -To study change in pattern of stool sensitivity in 2 time periods 1st January 2008 to 31st December 2014 and 1st January 2015 to 31st December 2020 -Correlation of change in stool sensitivity pattern in the first 100 days with OS -Correlation of change in stool sensitivity pattern in the first 100 days with gut GVHD or any GVHD Timepoint: 3 months | — |
Countries
India
Contacts
Public ContactDr Keshav Garg
Advanced Centre for Treatment Research and Education in Cancer
Outcome results
None listed